Is WAT a good stock to buy? We came across a bullish thesis on Waters Corporation on The Wealth Dynasty Report’s Substack. In this article, we will summarize the bulls’ thesis on WAT. Waters Corporation’s share was trading at $301.88 as of May 4th. WAT’s trailing and forward P/E were 28.54 and 21.37 respectively according to Yahoo Finance.
Pixabay/Public Domain
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. WAT recently experienced a sharp selloff following its Q4 2025 results and the closing of its transformative merger with BD’s Biosciences and Diagnostic Solutions division, creating a compelling entry point into a high-quality analytical instruments business.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Despite near-term concerns around integration, the core Waters business remains fundamentally strong, generating $762 million in operating cash flow with industry-leading margins and a resilient model built on liquid chromatography, mass spectrometry, and thermal analysis tools. The company benefits from a highly recurring revenue base, with 57% of sales derived from consumables and service contracts, and a sticky customer base led by pharma and biopharma clients, which account for 58% of revenue.
Financially, Waters has demonstrated consistent profitability, with FY2025 non-GAAP EPS growing 11% to $13.13 and free cash flow conversion exceeding 100% of net income, highlighting exceptional cash generation. At current levels, the stock trades at approximately 24x earnings, a meaningful discount to its historical 38–42x range and below sector averages, despite maintaining ~59% gross margins and strong liquidity metrics, including a 1.53x current ratio.
The BD merger more than doubles revenue and introduces significant long-term synergies, positioning the combined entity for 10%+ EPS growth and substantial scale benefits. While integration and elevated leverage present short-term risks, robust cash flows provide a clear path to deleveraging. With secular tailwinds from pharma innovation, instrument replacement cycles, and expanding global demand, Waters offers an attractive risk-reward profile, where successful execution could drive meaningful multiple expansion and sustained shareholder returns.
Previously, we covered a bullish thesis on Thermo Fisher Scientific Inc. (TMO) by Kontra in October 2024, which highlighted the company’s positioning as a quality compounder driven by its diversified life sciences portfolio and strong competitive advantages. TMO’s stock price has depreciated by approximately 23.11% since our coverage. The Wealth Dynasty Report shares a similar view but emphasizes on Waters Corporation’s discounted valuation and integration-driven upside.
Waters Corporation is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 47 hedge fund portfolios held WAT at the end of the fourth quarter which was 42 in the previous quarter. While we acknowledge the risk and potential of WAT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than WAT and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
